Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Interest & Investment Income (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Interest & Investment Income for 9 consecutive years, with $4.9 million as the latest value for Q1 2026.

  • For Q1 2026, Interest & Investment Income fell 42.04% year-over-year to $4.9 million; the TTM value through Mar 2026 reached $24.9 million, down 32.77%, while the annual FY2025 figure was $28.5 million, 16.98% down from the prior year.
  • Interest & Investment Income hit $4.9 million in Q1 2026 for Bicycle Therapeutics, down from $5.9 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $10.6 million in Q3 2024 and bottomed at $218000.0 in Q1 2022.
  • Average Interest & Investment Income over 5 years is $5.1 million, with a median of $5.6 million recorded in 2024.
  • Year-over-year, Interest & Investment Income surged 8195.83% in 2022 and then crashed 42.97% in 2025.
  • Bicycle Therapeutics' Interest & Investment Income stood at $2.6 million in 2022, then surged by 137.82% to $6.3 million in 2023, then skyrocketed by 64.17% to $10.3 million in 2024, then plummeted by 42.97% to $5.9 million in 2025, then dropped by 17.0% to $4.9 million in 2026.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $4.9 million, $5.9 million, and $6.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.